Eckman James R, Hassell Kathryn L, Huggins Wayne, Werner Ellen M, Klings Elizabeth S, Adams Robert J, Panepinto Julie A, Hamilton Carol M
Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA.
Division of Hematology, Department of Internal Medicine, University of Colorado, Denver, Aurora, CO.
Blood Adv. 2017 Dec 15;1(27):2703-2711. doi: 10.1182/bloodadvances.2017010702. eCollection 2017 Dec 26.
Standard measures and common data elements for sickle cell disease (SCD) will improve the data quality and comparability necessary for cross-study analyses and the development of guidelines that support effective treatments and interventions. In 2014, the National Institutes of Health, National Heart, Lung, and Blood Institute (NHLBI) funded an Administrative Supplement to the PhenX Toolkit (consensus measures for Phenotypes and eXposures; https://www.phenxtoolkit.org/) to identify common measures to promote data comparability across SCD research. An 11-member Sickle Cell Disease Research and Scientific Panel provided guidance to the project, establishing a core collection of SCD-related measures and defining the scope of 2 specialty collections: (1) cardiovascular, pulmonary, and renal complications, and (2) neurology, quality-of-life, and health services. For each specialty collection, a working group of SCD experts selected high-priority measures using a consensus process that included scientific community input. The SCD measures were released into the Toolkit in August 2015. The 25 measures included in the core collection are recommended for use by all NHLBI-funded investigators performing human-subject SCD research. The 10 neurology, quality-of-life, and health services measures and 14 cardiovascular, pulmonary, and renal measures are recommended for use within these specialized research areas. For SCD and other researchers, PhenX measures will promote collaborations with clinicians and patients, facilitate cross-study analysis, accelerate translational research, and lead to greater understanding of SCD phenotypes and epigenetics. For clinicians, using PhenX measures will help elucidate the etiology, progression, and treatment of SCD, leading to improved patient care and quality of life.
镰状细胞病(SCD)的标准测量方法和通用数据元素将提高跨研究分析以及制定支持有效治疗和干预措施的指南所需的数据质量和可比性。2014年,美国国立卫生研究院下属的国家心脏、肺和血液研究所(NHLBI)为PhenX工具包(表型和暴露的共识测量;https://www.phenxtoolkit.org/)提供了一项行政补充资金,以确定促进SCD研究数据可比性的通用测量方法。一个由11名成员组成的镰状细胞病研究与科学小组为该项目提供指导,建立了与SCD相关测量方法的核心集合,并界定了2个专业集合的范围:(1)心血管、肺部和肾脏并发症,以及(2)神经学、生活质量和卫生服务。对于每个专业集合,一个由SCD专家组成的工作组采用包括科学界意见在内的共识流程选择了高优先级的测量方法。SCD测量方法于2015年8月发布到该工具包中。核心集合中包含的25项测量方法被推荐供所有由NHLBI资助的进行人体SCD研究的研究人员使用。10项神经学、生活质量和卫生服务测量方法以及14项心血管、肺部和肾脏测量方法被推荐在这些专业研究领域内使用。对于SCD研究人员和其他研究人员而言,PhenX测量方法将促进与临床医生和患者的合作,便于进行跨研究分析,加速转化研究,并加深对SCD表型和表观遗传学的理解。对于临床医生来说,使用PhenX测量方法将有助于阐明SCD的病因、进展和治疗方法,从而改善患者护理和生活质量。